Lancor Scientific’s live cancer screening tech proves global viability of blockchain-based platforms

It is the first device to use light to detect the state of electromagnetism in tissue. When tissue becomes cancerous, the magnetic profile of cells changes. Healthy tissue demonstrates a diamagnetic profile, whereas malignant tissue demonstrates a paramagnetic profile. 

The OMIS device takes advantage of the photoelectric effect in quantum physics. When light is shone onto tissue, the magnetic component of the reflected light from the tissue can determine how malignant it is. This also means that the device does not subject the patient to potentially dangerous ultraviolet, X-ray or microwave radiation. 

The patented technology is validated and CE marked for cervical cancer, following a number of clinical trials with partners, including the NHS, totalling approximately 2,000 people. It currently runs at 90% accuracy, compared to the 60% accuracy that Pap screening offers. With the use of AI removing biological noise from samples, trials are aiming to push for 97% accuracy. Costs can also be dramatically decreased. Pap and HPV cost £30-40, whereas a cervical cancer screening using OMIS costs between £5-10, approximately.

Lancor Scientific is currently aiming to validate the OMIS device to screen for a range of cancers in the future.

Aamir Butt, CEO of Lancor Scientific, has commented “Lancor Scientific has dedicated itself to making effective cancer screening available to everyone, everywhere. Our technology will help people to be screened earlier than ever before, so that they can receive necessary treatment, even before symptoms occur. Blockchain technology will provide a secure infrastructure to roll-out the device and Lancor Scientific platform.”